• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Quest Diagnostics launches patient-ordered COVID-19 antibody test

Quest Diagnostics launches patient-ordered COVID-19 antibody test

April 28, 2020 By Nancy Crotti

(Image from Quest Diagnostics)

Quest Diagnostics (NYSE:DGX) announced today that consumers can now order a COVID-19 antibody test it launched last week directly from the company, without visiting a doctor’s office.

The Secaucus, N.J.-based testing giant said consumers can purchase the antibody test service online for $119 through its QuestDirect business. They will be prompted to schedule an appointment for a blood draw at one of the 2,200 patient service centers Quest Diagnostics operates around the U.S. They must not have experienced symptoms of COVID-19 for at least 10 days; wear a face mask; and pass a contact-less temperature check.

The company is using tests developed for high-throughput environments, starting with one launched yesterday by Abbott and another by Euroimmun/PerkinElmer (NYSE:PKI). The Abbott received an Emergency Use Authorization from the FDA and the Euroimmun test has been released for use under an emergency FDA guidance updated March 16, 2020 but has and has not been reviewed by the FDA.

Each test request is reviewed and, if appropriate, an order for testing will be issued by a licensed physician working for PWNHealth, an independent national network of physicians is providing clinical oversight for QuestDirect. PWN will also deliver test results and post-test telehealth support to patients, according to Quest. Consumers may also speak with a physician about their results.

Test results are available within two days and may indicate exposure to and antibodies for  COVID-19, also known as SARS-CoV-2, according to the company. The FDA has said it’s unknown whether the development of antibodies to COVID-19 provides protection from re-infection, or how long such protection lasts. The serology antibody tests run by Quest Diagnostics are either approved by the FDA under an emergency use authorization, or were released for use under the FDA guidance, “Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency,” updated March 16, 2020, and have not been reviewed by the FDA, the company said.

“With the introduction of this test and service, Quest is making it easy for people to access quality testing for antibodies to the virus which causes COVID-19, with access to physician interpretation and steering into needed care,” said Dr. Jay Wohlgemuth, SVP and chief medical officer for Quest Diagnostics, in a news release. “While the science on COVID-19 is evolving, testing for antibodies may identify people who have likely been exposed to COVID-19 and might have mounted an immune response to the virus.  Our goal is to empower individuals and their physicians to make informed decisions about their risk of infection and of spreading the virus.”

Quest said it provides data on COVID-19 testing to federal and state public health authorities, including the Centers for Disease Control and Prevention, and participates in studies with government and private institutions.

According to the FDA, results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.

This article has been updated with information about specific tests Quest Diagnostics will use for COVID-19 antibody detection.

Filed Under: Business/Financial News, Diagnostics, Digital Health, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Abbott, euroimmun, FDA, PerkinElmer Inc., PWN Health, Quest Diagnostics Inc.

More recent news

  • FDA warns of Philips ultrasound issues after four patient deaths
  • FDA approves Gore bridging stent graft in complex aortic aneurysms
  • Steris inks $2.1B deal for operating room supplier Xodus Medical
  • Insulet’s Omnipod Discover data platform begins full US rollout
  • Siemens Healthineers exits general ultrasound to focus on cardiac imaging

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy